These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 5326508)

  • 1. Cognitive test performance under LSD-25, placebo and isolation.
    Goldberger L
    J Nerv Ment Dis; 1966 Jan; 142(1):4-9. PubMed ID: 5326508
    [No Abstract]   [Full Text] [Related]  

  • 2. Placebo reactions in a study of lysergic acid diethylamide (LSD-25).
    LINTON HB; LANGS RJ
    Arch Gen Psychiatry; 1962 May; 6():369-83. PubMed ID: 14465662
    [No Abstract]   [Full Text] [Related]  

  • 3. Lysergic acid diethylamide (LSD-25). 38. Comparison with action of methysergide and psilocybin on test subjects.
    Abramson HA; Rolo A
    J Asthma Res; 1965 Sep; 3(1):81-96. PubMed ID: 5318626
    [No Abstract]   [Full Text] [Related]  

  • 4. Lysergic acid diethylamide tartrate (LSD-25) dosage levels, group differences and social interaction.
    Cheek FE; Holstein CM
    J Nerv Ment Dis; 1971 Aug; 153(2):133-47. PubMed ID: 5572106
    [No Abstract]   [Full Text] [Related]  

  • 5. Performance on some objective tests under LSD-25.
    BARENDREGT JT
    Fortschr Psychosom Med; 1960; 1():217-9. PubMed ID: 13796717
    [No Abstract]   [Full Text] [Related]  

  • 6. Lysergic acid diethylamide (LSD-25) and schizophrenic reactions. A comparative study.
    Langs RJ; Barr HL
    J Nerv Ment Dis; 1968 Aug; 147(2):163-72. PubMed ID: 5677324
    [No Abstract]   [Full Text] [Related]  

  • 7. Characterizing the psychological state produced by LSD.
    Katz MM; Waskow IE; Olsson J
    J Abnorm Psychol; 1968 Feb; 73(1):1-14. PubMed ID: 5639999
    [No Abstract]   [Full Text] [Related]  

  • 8. Factors contributing to unexpected reactions in two human drug-placebo experiments.
    Reed CF; Witt PN
    Confin Psychiatr; 1965; 8(2):57-68. PubMed ID: 5318256
    [No Abstract]   [Full Text] [Related]  

  • 9. Reaction time ("mental set") in control and chronic schizophrenic subjects and in postaddicts under placebo, LSD-25, morphine, pentobarbital and amphetamine.
    Wikler A; Haertzen CA; Chessick RD; Hill HE; Pescor FT
    Psychopharmacologia; 1965 May; 7(6):423-43. PubMed ID: 5319301
    [No Abstract]   [Full Text] [Related]  

  • 10. [LSD intoxication and change of attitude].
    Hrůza V; Kratochvíl S; Fanfulová E
    Cesk Psychiatr; 1969 Aug; 65(4):218-23. PubMed ID: 4896905
    [No Abstract]   [Full Text] [Related]  

  • 11. Stability of earliest memories under LSD-25 and placebo.
    Langs RJ
    J Nerv Ment Dis; 1967 Mar; 144(3):171-84. PubMed ID: 6026527
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of LSD-25 on tests of personality.
    BRENGELMANN JC
    J Ment Sci; 1958 Oct; 104(437):1226-36. PubMed ID: 13621172
    [No Abstract]   [Full Text] [Related]  

  • 13. The effects of LSD-25 on creativity and tolerance to regression.
    Zegans LS; Pollard JC; Brown D
    Arch Gen Psychiatry; 1967 Jun; 16(6):740-9. PubMed ID: 5338679
    [No Abstract]   [Full Text] [Related]  

  • 14. Age and effect of LSD-25 on pupil size and kneejerk threshold. Studies in chronic schizophrenic and nonpsychotic subjects.
    Wikler A; Rosenberg DE; Hawthorne JD; Cassidy TM
    Psychopharmacologia; 1965 Jan; 7(1):44-56. PubMed ID: 5318923
    [No Abstract]   [Full Text] [Related]  

  • 15. The paradoxical psychological effects of lysergic acid diethylamide (LSD).
    Carhart-Harris RL; Kaelen M; Bolstridge M; Williams TM; Williams LT; Underwood R; Feilding A; Nutt DJ
    Psychol Med; 2016 May; 46(7):1379-90. PubMed ID: 26847689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subjective reports of lysergic acid experiences in a context of psychological test performance.
    COHEN S; FICHMAN L; GROVER EISNER B
    Am J Psychiatry; 1958 Jul; 115(1):30-5. PubMed ID: 13545391
    [No Abstract]   [Full Text] [Related]  

  • 17. Modification of autistic behavior with LSD-25.
    Simmons JQ; Leiken SJ; Lovaas OI; Schaeffer B; Perloff B
    Am J Psychiatry; 1966 May; 122(11):1201-11. PubMed ID: 5325567
    [No Abstract]   [Full Text] [Related]  

  • 18. THE INTERACTION OF LSD AND SENSORY DEPRIVATION: PHYSIOLOGICAL CONSIDERATIONS.
    COHEN S; EDWARDS AE
    Recent Adv Biol Psychiatry; 1963; 6():139-44. PubMed ID: 14282716
    [No Abstract]   [Full Text] [Related]  

  • 19. Chronic intraventricular administration of lysergic acid diethylamide (LSD) affects the sensitivity of cortical cells to monocular deprivation.
    McCall MA; Tieman DG; Hirsch HV
    Brain Res; 1982 Nov; 250(2):301-8. PubMed ID: 7171990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic trial of lysergic Acid diethylamide (LSD) and thioridazine in chronic schizophrenia.
    Shirvaikar RV; Kelkar YW
    Neurol India; 1966; 14(2):97-101. PubMed ID: 5330728
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.